Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older

This publication has 48 references indexed in Scilit:

• Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy
  Cancer, 2005
• Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission
  Cancer, 2005
• A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
  Blood, 2004
• Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
  Blood, 2002
• Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
  Blood, 2002
• Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies
  Blood, 2002
• Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
  Blood, 2001
• Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
  Blood, 2001
• Management of Acute Myeloid Leukemia in Elderly Patients
  Journal of Clinical Oncology, 1999
• A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
  Blood, 1998